II. Management: Strategy

  1. Written action plan
    1. Based on symptoms or Peak Expiratory Flow
  2. Long term use of Inhaled Corticosteroids
    1. Decrease airway inflammation
    2. Most effective medication for long-term control
  3. Intermittent and cautious use of Inhaled Beta Agonist
    1. Avoid more than 4 times per day
  4. Treat other possible confounding factors
    1. Gastroesophageal Reflux Disease
    2. Chronic Sinusitis
    3. Allergic Rhinitis
  5. Prevent Exercise-induced and cold-induced Asthma
    1. Consider Sodium cromoglycate

III. Management: Approach to Uncontrolled Symptoms

  1. Indicators of uncontrolled Asthma
    1. Frequent use and early refills of rescue Inhaler
    2. Rescue Inhaler use more than twice weekly
    3. Nighttime symptoms more than twice monthly (over age 5)
  2. Assessment
    1. Consider Asthma control test (see resources below)
    2. Review Asthma medication use and Asthma Action Plan
    3. Patient's should demonstrate use of their rescue Inhaler (and consider with spacer)
  3. Protocol
    1. Advance medications per stepped care and Asthma grouping (see below)
    2. For more significant symptoms start at a higher step (e.g. step 3 or 4)
    3. Re-evaluate every 2-4 weeks and step-up or step down management
    4. Advance stepped care for short-acting Bronchodilator more than twice weekly for acute symptom control
  4. Step 1
    1. Inhaled short-acting Bronchodilator (SABA)
  5. Step 2
    1. Inhaled short-acting Bronchodilator (SABA)
    2. Add low dose Inhaled Corticosteroid (ICS)
  6. Step 3
    1. Inhaled short-acting Bronchodilator (SABA)
    2. Continue low dose Inhaled Corticosteroid (ICS)
    3. Add long-acting Bronchodilator (LABA)
      1. Alternative: Change low dose to moderate dose Inhaled Corticosteroid (ICS)
  7. Step 4
    1. Inhaled short-acting Bronchodilator (SABA)
    2. Change to Moderate dose Inhaled Corticosteroid (ICS)
    3. Long-acting Bronchodilator (LABA)
  8. Step 5
    1. Inhaled short-acting Bronchodilator (SABA)
    2. Change to High dose Inhaled Corticosteroid (ICS)
    3. Long-acting Bronchodilator (LABA)
  9. Step 6
    1. Inhaled short-acting Bronchodilator (SABA)
    2. High dose Inhaled Corticosteroid (ICS)
    3. Long-acting Bronchodilator (LABA)
    4. Add Oral Systemic Corticosteroids (or consider Omalizumab in patients with allergies)
  10. Additional measures
    1. Allergen Control
    2. Leukotriene Receptor Antagonist (LTRA)
    3. Consider Allergen Immunotherapy

IV. Management: Grouping (NIH recommendations)

  1. Intermittent Asthma
    1. Occasional exacerbations (Less than twice per week)
  2. Mild Persistent Asthma
    1. Frequent exacerbations (>twice weekly, but not daily)
  3. Moderate Persistent Asthma
    1. Daily symptoms with daily Beta Agonist use
  4. Severe Persistent Asthma
    1. Continuous Symptoms and frequent exacerbations

V. Management: Available Medications

  1. All aerosolized Inhalers should be used with a spacer
    1. Without a spacer, medication delivery is inadequate
    2. See Spacer Devices for Asthma Inhalers
  2. Inhaled Corticosteroids
    1. Most important agents in reactive airway disease
    2. Should be first-line agent in all persistent Asthma
    3. Maximize steroid dose before adding other agents
    4. Ducharme (2002) BMJ 324:1545-8 [PubMed]
  3. Mast Cell Stabilizers
    1. Agents
      1. Cromolyn Sodium (Intal)
      2. Nedocromil (Tilade)
    2. Indications
      1. Alternative antiinflammatory drug for age <5 years
      2. Prophylactic agent for
        1. Exercise induced Asthma
        2. Cold-air-induced Bronchial Asthma
  4. Beta Adrenergic Agonist
    1. Short acting Rescue Inhaler (e.g. Albuterol)
    2. Long acting scheduled Inhaler (e.g. Serevent)
      1. Indicated for moderate to Severe Asthma
      2. Use as adjunct to Inhaled Corticosteroids
  5. Anticholinergics: Ipratropium Bromide (Atrovent)
  6. Leukotriene Receptor Antagonist (e.g. Montelukast)
    1. Indicated as adjunct for moderate to Severe Asthma
    2. Do not use as a first line agent in most cases
      1. Exception: Preschool children with Allergic Asthma
        1. Straub (2005) Chest 127:509-14 [PubMed]
  7. Theophyllines
    1. Rare use in current Asthma Management
  8. Anti-IgE Therapy (Omalizumab)
    1. Indicated in severe refractory (Step 5-6) Asthma with IgE levels >75
    2. Subcutaneous Injection every 2-4 weeks

VII. Prevention

  1. See Asthma Education
  2. Influenza Vaccine yearly
    1. Protection lags shot by 2 weeks

VIII. Resources

  1. Guidelines for the diagnosis and management of Asthma, expert panel 3 (2007)
    1. https://www.nhlbi.nih.gov/health-pro/guidelines/current/asthma-guidelines/full-report

IX. References

  1. (2014) Presc Lett 21(12): 67-8
  2. Kalister (2001) West J Med 174:415-20 [PubMed]

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Ontology: Asthma management (C1318955)

Definition (NIC) Identification, treatment, and prevention of reactions to inflammation/constriction in the airway passages
Concepts Health Care Activity (T058)
SnomedCT 406162001
English Asthma Management, care asthma, management asthma, asthma management, asthma care, Asthma care, Asthma management (regime/therapy), Asthma management
Spanish manejo del asma (régimen/tratamiento), manejo del asma